A New Era of Drug Discovery with AI

Recent news highlights GSK's exploration of new possibilities in drug discovery by leveraging artificial intelligence (AI). They are studying how specific gene functions are regulated in human cells and what changes occur when cells are treated with drugs. Through this, they are generating large-scale data to identify disease causes and therapeutic targets for new drug development.

GSK and Relation Therapeutics Ink Collaboration Deal

On the 30th (local time), the UK-based AI biotech company Relation Therapeutics and GSK signed a research collaboration agreement valued at up to $110 million. This agreement includes an upfront payment and milestone payments based on research achievements, though specific amounts have not been disclosed. The collaboration focuses on generating data to predict how drug candidates, through AI, might impact genes and cellular functions related to diseases.

Adopting a Multi-Omics Approach

In this research, Relation plans to generate extensive 'cellular response data' by measuring internal cellular changes after regulating gene functions in human cells or treating them with drugs. This data will be used to train AI models to predict the efficacy of drug candidates. Furthermore, they will track how cellular responses evolve over time using automated experimental techniques.

• Measuring various biological information, including gene expression
• Analyzing diverse changes through a multi-omics approach

Identifying Reliable Therapeutic Targets

In drug development, selecting therapeutic targets not directly linked to a disease increases the probability of failure during clinical trials. GSK and Relation aim to enhance the precision of analyzing biological pathways involved in diseases and increase the reliability of therapeutic targets by training AI with data obtained from actual human cells. This agreement emphasizes data generation and AI model development for early-stage drug discovery, with specific diseases and targets yet to be disclosed.

Future Outlook

Relation is currently conducting drug research utilizing AI and single-cell analysis technologies in the fields of immune, metabolic, and bone diseases. This is not the first collaboration between GSK and Relation; they previously entered into a research agreement in 2024 to discover new therapeutic targets for fibrotic diseases and osteoarthritis. This latest agreement is seen as a follow-up collaboration to strengthen the foundation for large-scale cellular data and AI-driven insights applicable to various drug research initiatives.